Informed Prostate Cancer Patient Support

Why We Can't "Cure" Cancer One Name, Many Diseases: How Genomics Is Rewriting Prostate Cancer Treatment Why "prostate cancer" is really a family of related illnesses — and what that means for your treatment plan Informed Prostate Cancer Support Group (IPCSG) Newsletter — Patient Education Series For most of medical history, prostate cancer was treated as one disease with one playbook: watch it, cut it out, radiate it, or starve it of testosterone. That playbook still matters. But over the last decade, something fundamental has shifted in how oncologists actually think about the disease sitting inside your prostate, or the one that has spread beyond it. The single word "prostate cancer" turns out to be a label covering a family of biologically distinct illnesses, each with its own genetic fingerprint, its own typical behavior, and — increasingly — its own matched treatment. This article walks through what that means in plain language, wha...

An Automated, Pathologist-free Gleason Grade Stratifies Disease-free Interval Comparably to Expert Grading from a Single Out-of-distribution Slide | medRxiv How Artificial Intelligence Is Changing the Way Your Biopsy Is Read Informed Prostate Cancer Support Group The Informed Patient July 2026  |  Educational Newsletter for Prostate Cancer Patients and Families AI tools that grade prostate cancer as well as expert pathologists are winning FDA approval, entering clinical guidelines, and moving toward routine use — and a new preprint study shows they can now do it without a pathologist in the room at all. By the IPCSG Educational Committee  |  Reviewed June 2026 If you have been diagnosed with prostate cancer, the single most important number in your medical record — your Gleason grade — was almost certainly assigned by a pathologist staring through a microscope (or these days, a computer screen) at thin slices of you...

Biochemical recurrence after radical prostatectomy: Where do we stand to? | Prostate Cancer and Prostatic Diseases Understanding Biochemical Recurrence After Prostate Surgery IPCSG Educational Newsletter — Research Digest Series June 2026 • Prepared for the Informed Prostate Cancer Support Group Bottom Line Up Front (BLUF)   Rising PSA after a radical prostatectomy — called biochemical recurrence, or BCR — affects up to half of all men within a decade of surgery, but it does not mean the cancer has spread or that the situation is hopeless. The standard treatment, salvage radiotherapy directed at the surgical bed, cures many men, especially when given early at low PSA levels. New data confirm that adding hormone therapy, expanding radiation to the pelvis, and in some high-risk cases using next-generation androgen receptor blockers, can all improve outcomes further. PSMA-PET imaging is a powerful new tool, but at the very low PSA levels at which modern salvage trea...